This inventor holds 3 USPTO granted patents and 4 published patent applications and 1 EPO patent. Top assignee: Eli Lilly and Company. Active years: 2024-2026.
Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile
Company Filing History:
Years Active: 2024-2026
Title: Andrew Karl Dilger: Innovator in FGFR3 Inhibitor Compounds
Introduction
Andrew Karl Dilger is a notable inventor based in Golden, CO (US). He has made significant contributions to the field of medical research, particularly in the development of FGFR3 inhibitor compounds. With a total of 3 patents, his work focuses on addressing critical health issues.
Latest Patents
Dilger's latest patents include innovative compounds designed for the treatment of systemic sclerosis, fibrosis, achondroplasia, thanatophoric dysplasia, severe achondroplasia with developmental delay, acanthosis nigricans, muenke syndrome, and cancer. These compounds are formulated to provide therapeutic benefits for patients suffering from these conditions.
Career Highlights
Andrew Karl Dilger is currently employed at Eli Lilly and Company, where he continues to advance his research and development efforts. His work at this esteemed organization has allowed him to collaborate with other talented professionals in the field.
Collaborations
Some of his notable coworkers include Adedoyin David Abraham and Desta Doro Bume. Their collective expertise contributes to the innovative environment at Eli Lilly and Company.
Conclusion
Andrew Karl Dilger's contributions to the field of FGFR3 inhibitor compounds highlight his commitment to improving patient outcomes through innovative research. His work exemplifies the impact of dedicated inventors in the medical field.
Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile